Prognostic Impact of TERT Promoter Mutations in Adult-Type Diffuse Gliomas Based on WHO2021 Criteria
Author:
Lee Yujin1ORCID, Park Chul-Kee2, Park Sung-Hye34ORCID
Affiliation:
1. Department of Hospital Pathology, St. Vincent’s Hospital, The Catholic University of Korea College of Medicine, 93, Jungbu-daero, Paldal-gu, Suwon 16247, Gyeonggi-do, Republic of Korea 2. Department of Neurosurgery, Seoul National University College of Medicine, 103 Deahak-ro, Jongno-gu, Seoul 03080, Republic of Korea 3. Department of Pathology, Seoul National University College of Medicine, 103 Deahak-ro, Jongno-gu, Seoul 03080, Republic of Korea 4. Neuroscience Institute, Seoul National University College of Medicine, 103 Deahak-ro, Jongno-gu, Seoul 03080, Republic of Korea
Abstract
Mutation in the telomerase reverse transcriptase promoter (TERTp )is commonly observed in various malignancies, such as central nervous system (CNS) tumors, malignant melanoma, bladder cancer, and thyroid carcinoma. These mutations are recognized as significant poor prognostic factors for these tumors. In this investigation, a total of 528 cases of adult-type diffuse gliomas diagnosed at a single institution were reclassified according to the 2021 WHO classifications of CNS tumors, 5th edition (WHO2021). The study analyzed clinicopathological and genetic features, including TERTp mutations in each tumor. The impact of known prognostic factors on patient outcomes was analyzed through Kaplan–Meier survival and Cox regression analysis. TERTp mutations were predominantly identified in 94.1% of oligodendrogliomas (ODG), followed by 66.3% in glioblastoma, IDH-wildtype (GBM-IDHwt), and 9.2% of astrocytomas, IDH-mutant (A-IDHm). When considering A-IDHm and GBM as astrocytic tumors (Group 1) and ODGs (Group 2), TERTp mutations emerged as a significant adverse prognostic factor (p = 0.013) in Group 1. However, within each GBM-IDHwt and A-IDHm, the presence of TERTp mutations did not significantly impact patient prognosis (p = 0.215 and 0.268, respectively). Due to the high frequency of TERTp mutations in Group 2 (ODG) and their consistent prolonged survival, a statistical analysis to evaluate their impact on overall survival was deemed impractical. When considering MGMTp status, the combined TERTp-mutated and MGMTp-unmethylated group exhibited the worst prognosis in OS (p = 0.018) and PFS (p = 0.034) of GBM. This study confirmed that the classification of tumors according to the WHO2021 criteria effectively reflected prognosis. Both uni- and multivariate analyses in GBM, age, MGMTp methylation, and CDKN2A/B homozygous deletion were statistically significant prognostic factors while in univariate analysis in A-IDHm, grade 4, the Ki-67 index and MYCN amplifications were statistically significant prognostic factors. This study suggests that it is important to classify and manage tumors based on their genetic characteristics in adult-type diffuse gliomas.
Funder
Korea Health Technology R&D Project Korea Health Industry Development Institute Ministry of Health & Welfare Institute for Information & Communications Technology Promotion Korean government
Reference66 articles.
1. Telomeres and human disease: Ageing, cancer and beyond;Blasco;Nat. Rev. Genet.,2005 2. Telomeres and telomerase: Three decades of progress;Shay;Nat. Rev. Genet.,2019 3. Gaspar, T.B., Sa, A., Lopes, J.M., Sobrinho-Simoes, M., Soares, P., and Vinagre, J. (2018). Telomere maintenance mechanisms in cancer. Genes, 9. 4. Leao, R., Apolonio, J.D., Lee, D., Figueiredo, A., Tabori, U., and Castelo-Branco, P. (2018). Mechanisms of human telomerase reverse transcriptase (htert) regulation: Clinical impacts in cancer. J. Biomed. Sci., 25. 5. Plyasova, A.A., and Zhdanov, D.D. (2021). Alternative splicing of human telomerase reverse transcriptase (htert) and its implications in physiological and pathological processes. Biomedicines, 9.
|
|